Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on BioMarin Pharmaceutical (BMRN) today and set a price target of $108.00. The company’s shares closed last Friday at $78.00, close to its 52-week low of $68.25.
According to TipRanks.com, Schwartz is a 5-star analyst with an average return of 20.1% and a 52.8% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Chinook Therapeutics, and Sarepta Therapeutics.
Currently, the analyst consensus on BioMarin Pharmaceutical is a Moderate Buy with an average price target of $111.48, representing a 50.6% upside. In a report issued on November 3, Piper Sandler also maintained a Buy rating on the stock with a $123.00 price target.
See today’s analyst top recommended stocks >>
BioMarin Pharmaceutical’s market cap is currently $13.61B and has a P/E ratio of 108.40. The company has a Price to Book ratio of 5.05.
Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BMRN in relation to earlier this year. Last month, Elaine Heron, a Director at BMRN bought 15,000 shares for a total of $397,350.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
